156 related articles for article (PubMed ID: 33287933)
1. Immunohistochemical expression of ATRX in gliomas.
Jalal JA; Rowandizy AIS; Ismael AT
Cell Mol Biol (Noisy-le-grand); 2020 Aug; 66(7):131-135. PubMed ID: 33287933
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of MGMT in Gliomas.
Jalal JA
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):20-24. PubMed ID: 33040807
[TBL] [Abstract][Full Text] [Related]
3. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
[TBL] [Abstract][Full Text] [Related]
4. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
5. ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset.
Purkait S; Miller CA; Kumar A; Sharma V; Pathak P; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Fulton RS; Kale SS; Dahiya S; Sarkar C
Brain Pathol; 2017 Mar; 27(2):138-145. PubMed ID: 26833422
[TBL] [Abstract][Full Text] [Related]
6. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
[TBL] [Abstract][Full Text] [Related]
8. Perfusion MRI grading diffuse gliomas: Impact of permeability parameters on molecular biomarkers and survival.
Hilario A; Hernandez-Lain A; Sepulveda JM; Lagares A; Perez-Nuñez A; Ramos A
Neurocirugia (Astur : Engl Ed); 2019; 30(1):11-18. PubMed ID: 30143443
[TBL] [Abstract][Full Text] [Related]
9. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
11. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
[No Abstract] [Full Text] [Related]
12. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
14. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
15. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of ABCG2 in human malignant glioma].
Chu L; Huang Q; Zhai DZ; Zhu Q; Huo HM; Dong J; Qian ZY; Wang AD; Lan Q; Gao YL
Ai Zheng; 2007 Oct; 26(10):1090-4. PubMed ID: 17927879
[TBL] [Abstract][Full Text] [Related]
17. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
[No Abstract] [Full Text] [Related]
18. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
19. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
20. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]